"Pathological mechanisms have already manifested by the time of diagnosis causing irreversible damage to maternal and fetal systems. There is a need then to identify early molecular markers that identify mothers at risk before the onset of clinical symptoms allowing health care professionals to take preventative measures and prevent the placenta from becoming hypoxic. Preeclampsia is a complex multisystem disorder that involves the miscommunication between mother and fetus; it has been suggested that there are three potential origins to this pathology: fetal, maternal or a contribution from both. As a result, a single biomarker may not be capable of identifying ill women at risk. An accurate and early biomarker is essential to determining the most appropriate treatment plan.
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society. OMICS Group also organizing 3000+ International Scientific Conferences and events yearly all over the world with the support of 1000+ Scientific associations worldwide.
Citation: Wong F, Cox B (2014) Proteomics Analysis of Preeclampsia, a systematic Review of Maternal and Fetal Compartments. J Proteomics BioinformS10: 001."
Last date updated on January, 2021